Treatment of bipolar disorder: The evolving role of atypical antipsychotics

American Journal of Managed Care

Volumn 13, Issue 11 SUPPL. 7, 2007, Pages

  Perlis, Roy H ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE; CARBAMAZEPINE; CHLORPROMAZINE; CLOZAPINE; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; FLUOXETINE PLUS OLANZAPINE; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LAMOTRIGINE; LITHIUM; LITHIUM CARBONATE; MOOD STABILIZER; OLANZAPINE; PLACEBO; PROLACTIN; QUETIAPINE; RISPERIDONE; VALPROATE SEMISODIUM; VALPROIC ACID; ZIPRASIDONE;

ABDOMINAL OBESITY; ARTICLE; BIPOLAR DEPRESSION; BIPOLAR DISORDER; BIPOLAR I DISORDER; BIPOLAR II DISORDER; BIPOLAR MANIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DATA ANALYSIS; DIABETIC KETOACIDOSIS; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; DRUG TOLERABILITY; DYSLIPIDEMIA; EVIDENCE BASED MEDICINE; EXTRAPYRAMIDAL SYMPTOM; FOOD AND DRUG ADMINISTRATION; HUMAN; HYPERGLYCEMIA; HYPEROSMOLAR COMA; HYPERPROLACTINEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; LONG TERM CARE; METABOLIC DISORDER; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRACTICE GUIDELINE; PRIORITY JOURNAL; QT PROLONGATION; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; ARRHYTHMIAS, CARDIAC; BENZODIAZEPINES; BIPOLAR DISORDER; DIABETES MELLITUS, TYPE 2; DIBENZOTHIAZEPINES; DRUG EVALUATION; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; DYSLIPIDEMIAS; HUMANS; HYPERPROLACTINEMIA; PIPERAZINES; QUINOLONES; RISPERIDONE; THIAZOLES; TREATMENT OUTCOME; WEIGHT GAIN;

EID: 36849089668     PISSN: 10880224     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (83)

1. Nierenberg AA, Ostacher MJ, Borrelli DJ, et al. The integration of measurement and management for the treatment of bipolar disorder: a STEP-BD model of collaborative care in psychiatry. J Clin Psychiatry. 2006;67(suppl 11):3-7.
2. McElroy SL, Kotwal R, Keck PE Jr, Akiskal HS. Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations? J Affect Disord. 2005;86:107-127.
3. McElroy SL, Pope HG Jr, Keck PE Jr, et al. Are impulse-control disorders related to bipolar disorder? Compr Psychiatry. 1996;37:229-240.
4. Eskalith (lithium carbonate) product information. GlaxoSmithKline; September 2003. Available at: http://www.fda.gov/cder/foi/label/2004/ 16860slr074,1815 2slr020_eskalith_lbl.pdf. Accessed October 9, 2007.
5. Lithobid (lithium carbonate) product information. JDS Pharmaceuticals; March 2005. Available at: http://www.jdspharma.com/pdfs/LithobidPI.pdf. Accessed October 9, 2007.
6. Depakote (divalproex sodium) product information. Abbott Pharmaceuticals; October 2006. Available at: http://rxabbott.com/pdf/depakote.pdf. Accessed October 9, 2007.
7. Depakote ER (divalproex sodium extended release) product information. Abbott Pharmaceuticals; October 2006. Available at: http://www.rxabbott.com/pdf/ dep3.pdf. Accessed October 9, 2007.
8. Lamictal (lamotrigine) product information. GlaxoSmithKline; May 2007. Available at: http://us.gsk.com/products/assets/us_lamictal.pdf. Accessed October 9, 2007.
9. Equetro (carbamazepine extended release) product information. Validus Pharmaceuticals, Inc.; January 2007. Available at: http://www.equetro.com/Files/ PDFs/PrescribingInfo.pdf. Accessed October 9, 2007.
10. Thorazine (chlorpromazine) product information. Available at: http://www.fda.gov/cder/foi/label/2001/11120s86lbl.pdf. Accessed October 9, 2007.
11. Zyprexa (olanzapine) product information. Eli Lilly and Company; October 1, 2007. Available at: http://pi.lilly.com/us/zyprexa-pi.pdf. Accessed October 9, 2007.
12. Risperdal (risperidone) product information. Janssen; August 2007. Available at: http://www.risperdal.com/risperdal/shared/pi/risperdal.pdf. Accessed October 9, 2007.
13. Seroquel (quetiapine) product information. AstraZeneca; July 2007. Available at: http://www.astrazeneca-us.com/pi/seroquel.pdf. Accessed October 9, 2007.
14. Geodon (ziprasidone) product information. Pfizer; March 2007. Available at: http://www.pfizer.com/pfizer/download/uspi_geodon.pdf. Accessed October 9, 2007.
15. Ability (aripiprazole) product information. Otsuka Pharmaceutical Company; November 2006. Available at: http://www.bms.com/cgibin/anybin.pl?sql= select%20PPI%20from%20TB_PRODUCT_PPI%20where%20PPI_SEQ=101&key=PPI. Accessed October 9, 2007.
16. Symbyax (olanzapine and fluoxetine) product information. Eli Lilly and Company; October 1, 2007. Available at: http://pi.lilly.com/us/symbyax-pi.pdf. Accessed October 9, 2007.
17. American Psychiatric Association. Practice guideline for the treatment of patients with bipolar disorder (revision). Am J Psychiatry. 2002;159(4 suppl):1-50.
18. Available online as: Hirschfeld RMA, Bowden CL, Gitlin MJ, et al. Practice Guideline for the Treatment of Patients with Bipolar Disorder, Second Edition. American Psychiatric Association; April 2002. Available at: http://www.psych.org/psych_pract/treatg/pg/prac_guide.cfm. Accessed October 9, 2007.
19. Perlis RH. The role of pharmacologic treatment guidelines for bipolar disorder. J Clin Psychiatry. 2005;66(suppl 3):37-47.
20. Keck PE Jr, Perlis RH, Otto MW, et al. The Expert Consensus Guideline Series: treatment of bipolar disorder 2004. Postgrad Med. 2004 Dec;Special Report: 1-120. Available at: http://www.psychguides.com/ecgs15.php. Accessed October 9, 2007.
21. Suppes T, Dennehy EB, Hirschfeld RM, et al. The Texas implementation of medical algorithms: update to the algorithms for treatment of bipolar I disorder. J Clin Psychiatry. 2005;66:870-886.
22. Rush AJ, Crismon ML, Kashner TM, et al. Texas Medication Algorithm Project, phase 3 (TMAP-3): rationale and study design. J Clin Psychiatry. 2003;64:357-369.
23. Dennehy EB, Suppes T, Crismon ML, et al. Development of the Brief Bipolar Disorder Symptom Scale for patients with bipolar disorder. Psychiatry Res. 2004;127:137-145.
24. Crismon ML, Argo TR, Bendele SD, Suppes T. Texas Medication Algorithm Project Procedural Manual: Bipolar Disorder Algorithms. The Texas Department of State Health Services. 2007. Available at: http://www.dshs.state. tx.us/mhprograms/TIMABDman2007.pdf. Accessed October 9, 2007.
25. Tohen M, Sanger TM, McElroy SL, et al. Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group. Am J Psychiatry. 1999;156:702-709.
26. Tohen M, Jacobs TG, Grundy SL, et al. Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzapine HGGW Study Group. Arch Gen Psychiatry. 2000;57:841-849. Erratum in: Arch Gen Psychiatry. 2002;59:91.
27. Hirschfeld RM, Keck PE Jr, Kramer M, et al. Rapid antimanic effect of risperidone monotherapy: a 3-week multicenter, double-blind, placebo-controlled trial. Am J Psychiatry. 2004;161:1057-1065.
28. Khanna S, Vieta E, Lyons B, et al. Risperidone in the treatment of acute mania: double-blind, placebo-controlled study. Br J Psychiatry. 2005;187:229-234.
29. Bowden CL, Grunze H, Mullen J, et al. A randomized, double-blind, placebo-controlled efficacy and safety study of quetiapine or lithium as monotherapy for mania in bipolar disorder. J Clin Psychiatry. 2005;66:111-121.
30. McIntyre RS, Brecher M, Paulsson B, et al. Quetiapine or haloperidol as monotherapy for bipolar mania - a 12-week, double-blind, randomised, parallel-group, placebo-controlled trial. Eur Neuropsychopharmacol. 2005;15:573-585.
31. Vieta E, Mullen J, Brecher M, et al. Quetiapine monotherapy for mania associated with bipolar disorder: combined analysis of two international, doubleblind, randomised, placebo-controlled studies. Curr Med Res Opin. 2005;21:923-934.
32. Keck PE Jr, Versiani M, Potkin S, et al. Ziprasidone in the treatment of acute bipolar mania: a three-week, placebo-controlled, double-blind, randomized trial. Am J Psychiatry. 2003;160:741-748.
33. Potkin SG, Keck PE Jr, Segal S, et al. Ziprasidone in acute bipolar mania: a 21-day randomized, doubleblind, placebo-controlled replication trial. J Clin Psychopharmacol. 2005;25:301-310.
34. Sachs G, Sanchez R, Marcus R, et al. Aripiprazole in the treatment of acute manic or mixed episodes in patients with bipolar I disorder: a 3-week placebo-controlled study. J Psychopharmacol. 2006;20:536-546.
35. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry. 2003;160:1651-1658.
36. Berk M, Ichim L, Brook S. Olanzapine compared to lithium in mania: a double-blind randomized controlled trial. Int Clin Psychopharmacol. 1999;14:339-343.
37. Segal J, Berk M, Brook S. Risperidone compared with both lithium and haloperidol in mania: a double-blind randomized controlled trial. Clin Neuropharmacol. 1998;21:176-180.
38. Zajecka JM, Weisler R, Sachs G, et al. A comparison of the efficacy, safety, and tolerability of divalproex sodium and olanzapine in the treatment of bipolar disorder. J Clin Psychiatry. 2002;63:1148-1155.
39. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003;60:1218-1226.
40. Smulevich AB, Khanna S, Eerdekens M, et al. Acute and continuation risperidone monotherapy in bipolar mania: a 3-week placebo-controlled trial followed by a 9-week double-blind trial of risperidone and haloperidol. Eur Neuropsychopharmacol. 2005;15:75-84.
41. Tohen M, Baker RW, Altshuler LL, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002;159:1011-1017.
42. Vieta E, Bourin M, Sanchez R, et al. Effectiveness of aripiprazole v. haloperidol in acute bipolar mania: double-blind, randomised, comparative 12-week trial. Br J Psychiatry. 2005;187:235-242.
43. Tohen M, Chengappa KN, Suppes T, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002;59:62-69.
44. Sachs GS, Grossman F, Ghaemi SN, et al. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002;159:1146-1154.
45. Sachs G, Chengappa KN, Suppes T, et al. Quetiapine with lithium or divalproex for the treatment of bipolar mania: a randomized, double-blind, placebo-controlled study. Bipolar Disord. 2004;6:213-223.
46. Yatham LN, Paulsson B, Mullen J, Vagero AM. Quetiapine versus placebo in combination with lithium or divalproex for the treatment of bipolar mania. J Clin Psychopharmacol. 2004;24:599-606. Erratum in: J Clin Psychopharmacol. 2005;25:103. Erratum in: J Clin Psychopharmacol. 2005;25:201.
47. Delbello MP, Schwiers ML, Rosenberg HL, Strakowski SM. A double-blind, randomized, placebo-controlled study of quetiapine as adjunctive treatment for adolescent mania. J Am Acad Child Adolesc Psychiatry. 2002;41:1216-1223.
48. Yatham LN, Grossman F, Augustyns I, et al. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003;182:141-147. Erratum in: Br J Psychiatry. 2003;182:369.
49. Perlis RH, Baker RW, Zarate CA Jr, et al. Olanzapine versus risperidone in the treatment of manic or mixed states in bipolar I disorder: a randomized, double-blind trial. J Clin Psychiatry. 2006;67:1747-1753.
50. Perlis RH, Welge JA, Vornik LA, et al. Atypical antipsychotics in the treatment of mania: a meta-analysis of randomized, placebo-controlled trials. J Clin Psychiatry. 2006;67:509-516.
51. Tohen M, Vieta E, Calabrese J, et al. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60:1079-88. Erratum in: Arch Gen Psychiatry. 2004;61:176.
52. Shi L, Namjoshi MA, Swindle R, et al. Effects of olanzapine alone and olanzapine/fluoxetine combination on health-related quality of life in patients with bipolar depression: secondary analyses of a double-blind, placebo-controlled, randomized clinical trial. Clin Ther. 2004;26:125-34. Erratum in: Clin Ther. 2004;26:1934.
53. Brown EB, McElroy SL, Keck PE Jr, et al. A 7-week, randomized, double-blind trial of olanzapine/fluoxetine combination versus lamotrigine in the treatment of bipolar I depression. J Clin Psychiatry. 2006;67:1025-1033.
54. Calabrese JR, Keck PE Jr, Macfadden W, et al. A randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depression. Am J Psychiatry. 2005;162:1351-1360.
55. Thase ME, Macfadden W, Weisler RH, et al. Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study). J Clin Psychopharmacol. 2006;26:600-609.
56. Tohen M, Calabrese JR, Sachs GS, et al. Randomized, placebo-controlled trial of olanzapine as maintenance therapy in patients with bipolar I disorder responding to acute treatment with olanzapine. Am J Psychiatry. 2006;163:247-256.
57. Tohen M, Greil W, Calabrese JR, et al. Olanzapine versus lithium in the maintenance treatment of bipolar disorder: a 12-month, randomized, double-blind, controlled clinical trial. Am J Psychiatry. 2005;162:1281-1290.
58. Tohen M, Ketter TA, Zarate CA, et al. Olanzapine versus divalproex sodium for the treatment of acute mania and maintenance of remission: a 47-week study. Am J Psychiatry. 2003;160:1263-1271.
59. Namjoshi MA, Rajamannar G, Jacobs T, et al. Economic, clinical, and quality-of-life outcomes associated with olanzapine treatment in mania. Results from a randomized controlled trial. J Affect Disord. 2002;69:109-118.
60. Tohen M, Chengappa KN, Suppes T, et al. Relapse prevention in bipolar I disorder: 18-month comparison of olanzapine plus mood stabiliser v. mood stabiliser alone. Br J Psychiatry. 2004;184:337-345.
61. Altamura AC, Salvadori D, Madaro D, et al. Efficacy and tolerability of quetiapine in the treatment of bipolar disorder: preliminary evidence from a 12-month open-label study. J Affect Disord. 2003;76:267-271.
62. Versiani M, Keck P, Potkin S, et al. Efficacy and safety of ziprasidone in bipolar disorder: long-term data. Eur Psychiatry. 2005;20(suppl 1):S128. Abstract P-03-03.
63. Keck PE Jr, Calabrese JR, McQuade RD, et al. A randomized, double-blind, placebo-controlled 26-week trial of aripiprazole in recently manic patients with bipolar I disorder. J Clin Psychiatry. 2006;67:626-637.
64. Ramaswamy K, Masand PS, Nasrallah HA. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann Clin Psychiatry. 2006;18:183-194.
65. Seemuller F, Forsthoff A, Dittmann S, et al. The safety and tolerability of atypical antipsychotics in bipolar disorder. Expert Opin Drug Saf. 2005;4:849-868.
66. Marken PA, Pies RW. Emerging treatments for bipolar disorder: safety and adverse effect profiles. Ann Pharmacother. 2006;40:276-285.
67. Yumru M, Savas HA, Kurt E, et al. Atypical antipsychotics related metabolic syndrome in bipolar patients. J Affect Disord. 2007;98:247-252.
68. American Diabetes Association; American Psychiatric Association; American Association of Clinical Endocrinologists; North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care. 2004;27:596-601.
69. Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(suppl 1):1-93.
70. Haddad PM, Wieck A. Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs. 2004;64:2291-2314.
71. Montgomery J, Winterbottom E, Jessani M, et al. Prevalence of hyperprolactinemia in schizophrenia: association with typical and atypical antipsychotic treatment. J Clin Psychiatry. 2004;65:1491-1498.
72. Crawford AM, Beasley CM Jr, Tollefson GD. The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations. Schizophr Res. 1997;26:41-54.
73. Miceli JJ, Wilner KD, Hansen RA, et al. Single- and multiple-dose pharmacokinetics of ziprasidone under non-fasting conditions in healthy male volunteers. Br J Clin Pharmacol. 2000;49(suppl 1):5S-13S.
74. Goff DC, Posever T, Herz L, et al. An exploratory haloperidol-controlled dose-finding study of ziprasidone in hospitalized patients with schizophrenia or schizoaffective disorder. J Clin Psychopharmacol. 1998;18:296-304.
75. Small JG, Hirsch SR, Arvanitis LA, et al. Quetiapine in patients with schizophrenia. A high- and low-dose double-blind comparison with placebo. Seroquel Study Group. Arch Gen Psychiatry. 1997;54:549-557.
76. Kane JM, Carson WH, Saha AR, et al. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J Clin Psychiatry. 2002;63:763-771.
77. Pierre JM. Extrapyramidal symptoms with atypical antipsychotics: incidence, prevention and management. Drug Saf. 2005;28:191-208.
78. Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol. 2004;24:62-69.
79. Glassman AH. Schizophrenia, antipsychotic drugs, and cardiovascular disease. J Clin Psychiatry. 2005;66(suppl 6):5-10.
80. Nemeroff CB, Lieberman JA, Weiden PJ, et al. From clinical research to clinical practice: a 4-year review of ziprasidone. CNS Spectr. 2005;10:S1-S20.
81. Heinrich TW, Biblo LA, Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics. 2006;47:264-268.
82. Vieweg WV, Schneider RK, Wood MA. Torsade de pointes in a patient with complex medical and psychiatric conditions receiving low-dose quetiapine. Acta Psychiatr Scand. 2005;112:318-322.
83. Perlis RH, Keck PE. The Texas implementation of medication algorithms update for treatment of bipolar I disorder [commentary]. J Clin Psychiatry. 2005;66:818-820.